Hetero's Nirmacom World's 1st Generic Covid Oral Drug Paxlovid to Get WHO Pre-qualification

Hetero, India’s leading pharmaceutical company with the widest global reach, today announced the receipt of World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate nirmatrelvir. This is the first prequalification for a generic version of Pfizer’s COVID-19 oral antiviral drug

Related Keywords

India ,Charles Gore ,Vamsi Krishna Bandi ,Hetero Group Of Companies ,Pfizer ,World Health Organization Prequalification Of Medicines Program ,World Health Organization Prequalification ,Medicines Program ,Managing Director ,Hetero Group ,Medicines Patent Pool ,Executive Director ,Emergency Use Authorization ,Drugs Controller General ,Hetero 039s Nirmacom ,Etero 039s Nirmacom World 1st Generic Covid Oral Drug ,Etero 039s Nirmacom Paxlovid To Get Who Pre Qualification ,